Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
Sign Up to like & getrecommendations! Published in 2017 at "Oncoimmunology"
DOI: 10.1080/2162402x.2017.1338236
Abstract: ABSTRACT LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma… read more here.
Keywords: ltx 315; oncolytic peptide; model; abscopal effect ... See more keywords
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004129
Abstract: Background LTX-315 is an oncolytic peptide deriving from bovine lactoferrin, with the ability to induce cancer immunogenic cell death. However, the mechanism used by LTX-315 to trigger the antitumor immune response is still poorly understood.… read more here.
Keywords: cancer; ltx 315; oncolytic peptide; cancer immunity ... See more keywords
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-3435
Abstract: Purpose: LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced solid tumors. Patients… read more here.
Keywords: activity; solid tumors; cell; phase ... See more keywords
Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246093
Abstract: Simple Summary Radiofrequency ablation (RFA) is a favorite treatment approach for patients with liver cancer, one of the most common malignancies worldwide. However, incomplete RFA often occurs in irregular and medium-to-larger (>3 cm) hepatic tumors.… read more here.
Keywords: 315 residual; ltx 315; liver; residual tumors ... See more keywords
Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms231810558
Abstract: LTX-315 is a clinical-stage, anticancer peptide therapeutic that disrupts cancer cell membranes. Existing mechanistic knowledge about LTX-315 has been obtained from cell-based biological assays, and there is an outstanding need to directly characterize the corresponding… read more here.
Keywords: ltx 315; spectroscopy; anticancer peptide; membrane ... See more keywords
Understanding the Biophysical Interaction of LTX-315 with Tumoral Model Membranes
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24010581
Abstract: Host defense peptides are found primarily as natural antimicrobial agents among all lifeforms. These peptides and their synthetic derivatives have been extensively studied for their potential use as therapeutic agents. The most accepted mechanism of… read more here.
Keywords: interaction; ltx 315; 315 tumoral; understanding biophysical ... See more keywords
Aspirin for primary prevention.
Sign Up to like & getrecommendations! Published in 2020 at "Cleveland Clinic journal of medicine"
DOI: 10.3949/ccjm.87c.08005
Abstract: LTX-315 is a de novo designed peptide derived from a naturally occurring host defence peptide. LTX-315 has the potential to induce long-term specific protective immune responses by stimulating immune cells, inducing tumor cell lysis with… read more here.
Keywords: aspirin primary; immune; ltx 315; primary prevention ... See more keywords